, Volume 2, Issue 3, pp 465–470 | Cite as

Knock-in mouse models of Huntington’s disease

  • Liliana B. MenalledEmail author


Huntington’s disease is an autosomal dominant neurodegenerative disorder that is characterized by motor, cognitive, and psychiatric alterations. The mutation responsible for this fatal disease is an abnormally expanded and unstable CAG repeat within the coding region of the gene encoding huntingtin. Numerous mouse models have been generated that constitute invaluable tools to examine the pathogenesis of the disease and to develop and evaluate novel therapies. Among those models, knock-in mice provide a genetically precise reproduction of the human condition. The slow progression and early development of behavioral, pathological, cellular, and molecular abnormalities in knock-in mice make these animals valuable to understand the early pathological events triggered by the mutation. This review describes the different knock-in models generated, the insight gained from them, and their value in the development and testing of prospective treatments of the disease.

Key Words

Knock-in mouse models Huntington’s disease behavior huntingtin aggregates 


  1. 1.
    Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol 57: 369–384, 1998.PubMedCrossRefGoogle Scholar
  2. 2.
    Harper PS. Huntington’s disease. London: W.B. Saunders, 1996.Google Scholar
  3. 3.
    The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72: 971–983, 1993.CrossRefGoogle Scholar
  4. 4.
    Hickey MA, Chesselet MF. The use of transgenic and knock-in mice to study Huntington’s disease. Cytogenet Genome Res 100: 276–286, 2003.PubMedCrossRefGoogle Scholar
  5. 5.
    Duyao MP, Auerbach AB, Ryan A, Persichetti F, Barnes GT, McNeil SM, et al. Inactivation of the mouse Huntington’s disease gene homolog Hdh. Science 269: 407–410, 1995.PubMedCrossRefGoogle Scholar
  6. 6.
    Nasir J, Floresco SB, O’Kusky JR, Diewert VM, Richman JM, Zeisler J, et al. Targeted disruption of the Huntington’s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81: 811–823, 1995.PubMedCrossRefGoogle Scholar
  7. 7.
    Zeitlin S, Liu JP, Chapman DL, Papaioannou VE, Efstratiadis A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington’s disease gene homologue. Nat Genet 11: 155–163, 1995.PubMedCrossRefGoogle Scholar
  8. 8.
    White JK, Auerbach W, Duyao MP, Vonsattel JP, Gusella JF, Joyner AL, et al. Huntingtin is required for neurogenesis and is not impaired by the Huntington’s disease CAG expansion. Nat Genet 17: 404–410, 1997.PubMedCrossRefGoogle Scholar
  9. 8a.
    Dragatsis I, Levine MS, Zeitlin S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet 26: 300–306, 2000.PubMedCrossRefGoogle Scholar
  10. 9.
    Shelboume PF, Killeen N, Hevner RF, Johnston HM, Tecott L, Lewandoski M, et al. A Huntington’s disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. Hum Mol Genet 8: 763–774, 1999.CrossRefGoogle Scholar
  11. 10.
    Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90: 537–548, 1997.PubMedCrossRefGoogle Scholar
  12. 11.
    Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87: 493–506, 1996.PubMedCrossRefGoogle Scholar
  13. 12.
    Menalled LB, Chesselet MF. Mouse models of Huntington’s disease. Trends Pharmacol Sci 23: 32–39, 2002.PubMedCrossRefGoogle Scholar
  14. 13.
    Menalled LB, Sison JD, Dragatsis I, Zeitlin S, Chesselet MF. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington’s disease with 140 CAG repeats. J Comp Neurol 465: 11–26, 2003.PubMedCrossRefGoogle Scholar
  15. 14.
    Menalled LB, Sison JD, Wu Y, Olivieri M, Li XJ, Li H, et al. Early motor dysfunction and striosomal distribution of huntingtin micro-aggregates in Huntington’s disease knock-in mice. J Neurosci 22: 8266–8276, 2002.PubMedGoogle Scholar
  16. 15.
    Gusella JF, MacDonald ME. Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. Nat Rev Neurosci 1: 109–115, 2000.PubMedCrossRefGoogle Scholar
  17. 16.
    Smith MA, Brandt J, Shadmehr R. Motor disorder in Huntington’s disease begins as a dysfunction in error feedback control. Nature 403: 544–549, 2000.PubMedCrossRefGoogle Scholar
  18. 17.
    Wheeler VC, Gutekunst CA, Vrbanac V, Lebel LA, Schilling G, Hersch S, et al. Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice. Hum Mol Genet 11: 633–640, 2002.PubMedCrossRefGoogle Scholar
  19. 18.
    Lin CH, Tallaksen-Greene S, Chien WM, Cearley JA, Jackson WS, Crouse AB, et al. Neurological abnormalities in a knock-in mouse model of Huntington’s disease. Hum Mol Genet 10: 137–144, 2001.PubMedCrossRefGoogle Scholar
  20. 19.
    Levine MS, Klapstein GJ, Koppel A, Gruen E, Cepeda C, Vargas ME, et al. Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington’s disease. J Neurosci Res 58: 515–532, 1999.PubMedCrossRefGoogle Scholar
  21. 20.
    Wheeler VC, White JK, Gutekunst CA, Vrbanac V, Weaver M, Li XJ, et al. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum Mol Genet 9: 503–513, 2000.PubMedCrossRefGoogle Scholar
  22. 21.
    Liu YF, Deth RC, Devys D. SH3 domain-dependent association of huntingtin with epidermal growth factor receptor signaling complexes. J Biol Chem 272: 8121–8124, 1997.PubMedCrossRefGoogle Scholar
  23. 22.
    Passani LA, Bedford MT, Faber PW, McGinnis KM, Sharp AH, Gusella JF, et al. Huntingtin’s WW domain partners in Huntington’s disease post-mortem brain fulfill genetic criteria for direct involvement in Huntington’s disease pathogenesis. Hum Mol Genet 9: 2175–2182, 2000.PubMedCrossRefGoogle Scholar
  24. 23.
    Faber PW, Barnes GT, Srinidhi J, Chen J, Gusella JF, MacDonald ME. Huntingtin interacts with a family of WW domain proteins. Hum Mol Genet 7: 1463–1474, 1998.PubMedCrossRefGoogle Scholar
  25. 24.
    Sittler A, Walter S, Wedemeyer N, Hasenbank R, Scherzinger E, Eickhoff H, et al. SH3GL3 associates with the Huntingtin exon 1 protein and promotes the formation of polygln-containing protein aggregates. Mol Cell 2: 427–436, 1998.PubMedCrossRefGoogle Scholar
  26. 25.
    Qin ZH, Wang Y, Sapp E, Cuiffo B, Wanker E, Hayden MR, et al. Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. J Neurosci 24: 269–281, 2004.PubMedCrossRefGoogle Scholar
  27. 26.
    Wheeler VC, Auerbach W, White JK, Srinidhi J, Auerbach A, Ryan A, et al. Length-dependent gametic CAG repeat instability in the Huntington’s disease knock-in mouse. Hum Mol Genet 8: 115–122, 1999.PubMedCrossRefGoogle Scholar
  28. 27.
    Usdin MT, Shelboume PF, Myers RM, Madison DV. Impaired synaptic plasticity in mice carrying the Huntington’s disease mutation. Hum Mol Genet 8: 839–846, 1999.PubMedCrossRefGoogle Scholar
  29. 28.
    Martindale D, Hackam A, Wieczorek A, Ellerby L, Wellington C, McCutcheon K, et al. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat Genet 18: 150–154, 1998.PubMedCrossRefGoogle Scholar
  30. 29.
    Goldberg YP, Nicholson DW, Rasper DM, Kalchman MA, Koide HB, Graham RK, et al. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nat Genet 13: 442–449, 1996.PubMedCrossRefGoogle Scholar
  31. 30.
    Luesse HG, Schiefer J, Spruenken A, Puls C, Block F, Kosinski CM. Evaluation of R6/2 HD transgenic mice for therapeutic studies in Huntington’s disease: behavioral testing and impact of diabetes mellitus. Behav Brain Res 126: 185–195, 2001.PubMedCrossRefGoogle Scholar
  32. 31.
    Reddy PH, Charles V, Williams M, Miller G, Whetsell WO Jr, Tagle DA. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington’s disease. Philos Trans R Soc Lond B Biol Sci 354: 1035–1045, 1999.PubMedCrossRefGoogle Scholar
  33. 32.
    Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, Bates GP, et al. Characterization of progressive motor deficits in mice transgenic for the human Huntington’s disease mutation. J Neurosci 19: 3248–3257, 1999.PubMedGoogle Scholar
  34. 33.
    Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 12: 1555–1567, 2003.PubMedCrossRefGoogle Scholar
  35. 34.
    Yu ZX, Li SH, Evans J, Pillarisetti A, Li H, Li XJ. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington’s disease. J Neurosci 23: 2193–2202, 2003.PubMedGoogle Scholar
  36. 35.
    Li H, Li SH, Yu ZX, Shelbourne P, Li XJ. Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington’s disease mice. J Neurosci 21: 8473–8481, 2001.PubMedGoogle Scholar
  37. 36.
    Roizin L, Stellar S, Liu JC. Neuronal nuclear-cytoplasmic changes in Huntington’s chorea: electron microscope investigations. In: Advances in neurology (Chase TN, Wexler NS, Barbeau A, eds), pp 95–122. New York: Raven Press, 1979.Google Scholar
  38. 37.
    Hedreen JC, Folstein SE. Early loss of neostriatal striosome neurons in Huntington’s disease. J Neuropathol Exp Neurol 54: 105–120, 1995.PubMedCrossRefGoogle Scholar
  39. 38.
    Saudou F, Finkbeiner S, Devys D, Greenberg ME. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95: 55–66, 1998.PubMedCrossRefGoogle Scholar
  40. 39.
    Muchowski PJ, Ning K, D’Souza-Schorey C, Fields S. Requirement of an intact microtubule cytoskeleton for aggregation and inclusion body formation by a mutant huntingtin fragment. Proc Natl Acad Sci USA 99: 727–732, 2002.PubMedCrossRefGoogle Scholar
  41. 40.
    Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431: 805–810, 2004.PubMedCrossRefGoogle Scholar
  42. 41.
    Sapp E, Penney J, Young A, Aronin N, Vonsattel JP, DiFiglia M. Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease. J Neuropathol Exp Neurol 58: 165–173, 1999.PubMedCrossRefGoogle Scholar
  43. 42.
    Petersen A, Puschban Z, Lotharius J, NicNiocaill B, Wiekop P, O’Connor WT, et al. Evidence for dysfunction of the nigrostriatal pathway in the R6/1 line of transgenic Huntington’s disease mice. Neurobiol Dis 11: 134–146, 2002.PubMedCrossRefGoogle Scholar
  44. 43.
    Martin-Aparicio E, Yamamoto A, Hernandez F, Hen R, Avila J, Lucas JJ. Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington’ s disease. J Neurosci 21: 8772–8781, 2001.PubMedGoogle Scholar
  45. 44.
    Mende-Mueller LM, Toneff T, Hwang SR, Chesselet MF, Hook VY. Tissue-specific proteolysis of Huntingtin (htt) in human brain: evidence of enhanced levels of N- and C-terminal htt fragments in Huntington’s disease striatum. J Neurosci 21: 1830–1837, 2001.PubMedGoogle Scholar
  46. 45.
    Gafni J, Hermel E, Young JE, Wellington CL, Hayden MR, Ellerby LM. Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J Biol Chem 279: 20211–20220, 2004.PubMedCrossRefGoogle Scholar
  47. 46.
    Kennedy L, Shelboume PF. Dramatic mutation instability in HD mouse striatum: does polyglutamine load contribute to cell-specific vulnerability in Huntington’s disease? Hum Mol Genet 9: 2539–2544, 2000.PubMedCrossRefGoogle Scholar
  48. 47.
    Kennedy L, Evans E, Chen CM, Craven L, Detloff PJ, Ennis M, et al. Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis. Hum Mol Genet 12: 3359–3367, 2003.PubMedCrossRefGoogle Scholar
  49. 48.
    Wheeler VC, Lebel LA, Vrbanac V, Teed A, te Riele H, Mac-Donald ME. Mismatch repair gene Msh2 modifies the timing of early disease in Hdh(Q111) striatum. Hum Mol Genet 12: 273–281, 2003.PubMedCrossRefGoogle Scholar
  50. 49.
    Li H, Li SH, Johnston H, Shelboume PF, Li XJ. Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity. Nat Genet 25: 385–389, 2000.PubMedCrossRefGoogle Scholar
  51. 50.
    Reiner A, Albin RL, Anderson KD, D’Amato CJ, Penney JB, Young AB. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci USA 85: 5733–5737, 1988.PubMedCrossRefGoogle Scholar
  52. 51.
    Deng YP, Albin RL, Penney JB, Young AB, Anderson KD, Reiner A. Differential loss of striatal projection systems in Huntington’s disease: a quantitative immunohistochemical study. J Chem Neuroanat 27: 143–164, 2004.PubMedCrossRefGoogle Scholar
  53. 52.
    Sapp E, Ge P, Aizawa H, Bird E, Penney J, Young AB, et al. Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington’s disease using high resolution image analysis. Neuroscience 64: 397–404, 1995.PubMedCrossRefGoogle Scholar
  54. 53.
    Lee WC, Yoshihara M, Littleton JT. Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington’s disease. Proc Natl Acad Sci USA 101: 3224–3229, 2004.PubMedCrossRefGoogle Scholar
  55. 54.
    Li XJ, Li SH, Sharp AH, Nucifora FC Jr, Schilling G, Lanahan A, et al. A huntingtin-associated protein enriched in brain with implications for pathology. Nature 378: 398–402, 1995.PubMedCrossRefGoogle Scholar
  56. 55.
    Li SH, Gutekunst CA, Hersch SM, Li XJ. Interaction of huntingtin-associated protein with dynactin P150Glued. J Neurosci 18: 1261–1269, 1998.PubMedGoogle Scholar
  57. 56.
    Engelender S, Sharp AH, Colomer V, Tokito MK, Lanahan A, Worley P, et al. Huntingtin-associated protein 1 (HAP1) interacts with the p150Glued subunit of dynactin. Hum Mol Genet 6: 2205–2212, 1997.PubMedCrossRefGoogle Scholar
  58. 57.
    Szebenyi G, Morfini GA, Babcock A, Gould M, Selkoe K, Stenoien DL, et al. Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport. Neuron 40: 41–52, 2003.PubMedCrossRefGoogle Scholar
  59. 58.
    Lloret A, Janice E, Teed A, Hakky M, MacDonald ME, Wheeler VC. Genetic background modifies early disease events in the striatum of Huntington’s disease knock-in mice. Paper presented at the 54th Annual Meeting of the American Society of Human Genetics, Toronto, Ontario, Canada (Abstract 2203), 2004.Google Scholar
  60. 59.
    Cha JH. Transcriptional dysregulation in Huntington’s disease. Trends Neurosci 23: 387–392, 2000.PubMedCrossRefGoogle Scholar
  61. 60.
    Menalled L, Zanjani H, MacKenzie L, Koppel A, Carpenter E, Zeitlin S, et al. Decrease in striatal enkephalin mRNA in mouse models of Huntington’s disease. Exp Neurol 162: 328–342, 2000.PubMedCrossRefGoogle Scholar
  62. 61.
    Fossale E, Wheeler VC, Vrbanac V, Lebel LA, Teed A, Mysore JS, et al. Identification of a presymptomatic molecular phenotype in Hdh CAG knock-in mice. Hum Mol Genet 11: 2233–2241, 2002.PubMedCrossRefGoogle Scholar
  63. 62.
    Schaffar G, Breuer P, Boteva R, Behrends C, Tzvetkov N, Strippel N, et al. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol Cell 15: 95–105, 2004.PubMedCrossRefGoogle Scholar
  64. 63.
    Zucker B, Luthi-Carter R, Kama JA, Dunah AW, Stern EA, Fox JH, et al. Transcriptional dysregulation in striatal projection- and intemeurons in a mouse model of Huntington’s disease: neuronal selectivity and potential neuroprotective role of HAP1. Hum Mol Genet 14: 179–189, 2005.PubMedCrossRefGoogle Scholar
  65. 64.
    Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington’s disease. Science 293: 493–498, 2001.PubMedCrossRefGoogle Scholar
  66. 65.
    Gauthier LR, Charrin BC, Borrell-Pages M, Dompierre JP, Rangone H, Cordelieres FP, et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118: 127–138, 2004.PubMedCrossRefGoogle Scholar
  67. 66.
    Ferrer I, Goutan E, Marin C, Rey MJ, Ribalta T. Brain-derived neurotrophic factor in Huntington disease. Brain Res 866: 257–261, 2000.PubMedCrossRefGoogle Scholar
  68. 67.
    Gines S, Seong IS, Fossale E, Ivanova E, Trettel F, Gusella JF, et al. Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington’s disease knock-in mice. Hum Mol Genet 12: 497–508, 2003.PubMedCrossRefGoogle Scholar

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc 2005

Authors and Affiliations

  1. 1.PsychoGenics Inc.Tarrytown

Personalised recommendations